Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome
Abstract Background Reports of Guillain-Barré Syndrome (GBS) have emerged during the Coronavirus Disease 2019 (COVID-19) pandemic. This epidemiological and cohort study sought to investigate any causative association between COVID-19 infection and GBS.Methods The epidemiology of GBS cases reported via the UK National Immunoglobulin Database were studied from 2016-2019 and compared to cases reported during the COVID-19 pandemic. For the cohort study, members of the British Peripheral Nerve Society reported all cases of GBS during the pandemic. The clinical features, investigation findings and outcomes of COVID-19 (definite or probable) and non-COVID-19 associated GBS cases were compared.Results The UK GBS incidence from 2016-2019 was 1.65-1.88 per 100,000 people per year. GBS and COVID-19 incidence varied between regions and did not correlate (r = 0.06, 95% CI −0.56 to 0.63, p=0.86). GBS incidence fell between March and May 2020 compared to the same months of 2016-2019. Forty-seven GBS cases were included in the cohort study (13 definite, 12 probable COVID-19 and 22 non-COVID-19). There were no significant differences in the pattern of weakness, time to nadir, neurophysiology, CSF findings or outcome. Intubation was more frequent in the COVID-19+ve cohort (7/13, 54% vs 5/22, 23% in COVID negative) thought to be related directly to COVID-19 pulmonary involvement.Conclusions This study finds no epidemiological or phenotypic clues of SARS-CoV-2 being causative of GBS. GBS incidence has fallen during the pandemic which may be the influence of lockdown measures reducing transmission of GBS inducing pathogens such as Campylobacter jejuni and respiratory viruses..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 03. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keddie, S [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.07.24.20161471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018422314 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018422314 | ||
| 003 | DE-627 | ||
| 005 | 20230429081712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200727s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.24.20161471 |2 doi | |
| 035 | |a (DE-627)XBI018422314 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.07.24.20161471 | ||
| 035 | |a (biorXiv)10.1101/2020.07.24.20161471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Keddie, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Reports of Guillain-Barré Syndrome (GBS) have emerged during the Coronavirus Disease 2019 (COVID-19) pandemic. This epidemiological and cohort study sought to investigate any causative association between COVID-19 infection and GBS.Methods The epidemiology of GBS cases reported via the UK National Immunoglobulin Database were studied from 2016-2019 and compared to cases reported during the COVID-19 pandemic. For the cohort study, members of the British Peripheral Nerve Society reported all cases of GBS during the pandemic. The clinical features, investigation findings and outcomes of COVID-19 (definite or probable) and non-COVID-19 associated GBS cases were compared.Results The UK GBS incidence from 2016-2019 was 1.65-1.88 per 100,000 people per year. GBS and COVID-19 incidence varied between regions and did not correlate (r = 0.06, 95% CI −0.56 to 0.63, p=0.86). GBS incidence fell between March and May 2020 compared to the same months of 2016-2019. Forty-seven GBS cases were included in the cohort study (13 definite, 12 probable COVID-19 and 22 non-COVID-19). There were no significant differences in the pattern of weakness, time to nadir, neurophysiology, CSF findings or outcome. Intubation was more frequent in the COVID-19+ve cohort (7/13, 54% vs 5/22, 23% in COVID negative) thought to be related directly to COVID-19 pulmonary involvement.Conclusions This study finds no epidemiological or phenotypic clues of SARS-CoV-2 being causative of GBS. GBS incidence has fallen during the pandemic which may be the influence of lockdown measures reducing transmission of GBS inducing pathogens such as Campylobacter jejuni and respiratory viruses. | ||
| 700 | 1 | |a Pakpoor, J |e verfasserin |4 aut | |
| 700 | 1 | |a Mousele, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pipis, M |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, PM |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, M |e verfasserin |4 aut | |
| 700 | 1 | |a Record, CJ |e verfasserin |4 aut | |
| 700 | 1 | |a Keh, YS |e verfasserin |4 aut | |
| 700 | 1 | |a Fehmi, J |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, RW |e verfasserin |4 aut | |
| 700 | 1 | |a Bharambe, V |e verfasserin |4 aut | |
| 700 | 1 | |a Clayton, LM |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, C |e verfasserin |4 aut | |
| 700 | 1 | |a Price, O |e verfasserin |4 aut | |
| 700 | 1 | |a Wall, J |e verfasserin |4 aut | |
| 700 | 1 | |a Kiss-Csenki, A |e verfasserin |4 aut | |
| 700 | 1 | |a Rathnasabapathi, DP |e verfasserin |4 aut | |
| 700 | 1 | |a Geraldes, R |e verfasserin |4 aut | |
| 700 | 1 | |a Yermakova, T |e verfasserin |4 aut | |
| 700 | 1 | |a King-Robson, J |e verfasserin |4 aut | |
| 700 | 1 | |a Zosmer, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rajakulendran, S |e verfasserin |4 aut | |
| 700 | 1 | |a Nortley, R |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, CR |e verfasserin |4 aut | |
| 700 | 1 | |a Newman, E |e verfasserin |4 aut | |
| 700 | 1 | |a Nirmalananthan, N |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, G |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, AA |e verfasserin |4 aut | |
| 700 | 1 | |a Holt, J |e verfasserin |4 aut | |
| 700 | 1 | |a Lavin, TM |e verfasserin |4 aut | |
| 700 | 1 | |a Brennan, K |e verfasserin |4 aut | |
| 700 | 1 | |a Zandi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Jayaseelan, DL |e verfasserin |4 aut | |
| 700 | 1 | |a Pritchard, J |e verfasserin |4 aut | |
| 700 | 1 | |a Hadden, RDM |e verfasserin |4 aut | |
| 700 | 1 | |a Manji, H |e verfasserin |4 aut | |
| 700 | 1 | |a Willison, HJ |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, S |e verfasserin |4 aut | |
| 700 | 1 | |a Carr, AS |e verfasserin |4 aut | |
| 700 | 1 | |a Lunn, MP |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 03. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:03 |g month:02 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/brain/awaa433 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.24.20161471 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 03 |c 02 | ||
| 953 | |2 045F |a 570 | ||